Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II FOLFOX + panitumumab first-line with stop-and-go and reintroduction after maintenance progression in RAS wild-type metastatic colorectal adenocarcinoma
2017-001587-38Phase 2Active
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of panitumumab in colorectal adenocarcinoma, sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: time to failure of the strategy. Started Sep 2017; status: active.
02
Drugs
panitumumab
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on 2017-001587-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001587-38.